TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL